After some delay, I finally get around to discussing ORAL-Surveillance, a post-marketing safety study of tofacitinib for rheumatoid arthritis. It's an incredibly important trial that will likely affect how all of us practice for the foreseeable future. Link to paper: 

https://www.nejm.org/doi/full/10.1056/NEJMoa2109927